MX382192B - Composiciones de canabinoide y usos. - Google Patents

Composiciones de canabinoide y usos.

Info

Publication number
MX382192B
MX382192B MX2016010541A MX2016010541A MX382192B MX 382192 B MX382192 B MX 382192B MX 2016010541 A MX2016010541 A MX 2016010541A MX 2016010541 A MX2016010541 A MX 2016010541A MX 382192 B MX382192 B MX 382192B
Authority
MX
Mexico
Prior art keywords
glycol
composition
monohydric
polyhydric alcohol
cannabinoid compositions
Prior art date
Application number
MX2016010541A
Other languages
English (en)
Other versions
MX2016010541A (es
Inventor
Alex Hearn
Moira Bowdrey
Ritika Gupta
Original Assignee
Kind Consumer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kind Consumer Ltd filed Critical Kind Consumer Ltd
Publication of MX2016010541A publication Critical patent/MX2016010541A/es
Publication of MX382192B publication Critical patent/MX382192B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/20—Devices using solid inhalable precursors
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/20—Devices without heating means
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/60—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0093—Inhalators mechanically breath-triggered without arming or cocking, e.g. acting directly on the delivery valve
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición inhalable para el uso como un medicamento en el tratamiento de un sujeto en donde la composición comprende uno o más canabinoides o un derivado farmacéuticamente aceptable o sal de los mismos, un propelente, un alcohol monohídrico o polihídrico; y un glicol y/o éter de glicol, caracterizado en que la relación de alcohol monohídrico o polihídrico a glicol o éter de glicol en peso es de 6:1 a 1:1, en donde la composición se administra en la forma de un aerosol que tiene una fracción de partícula fina de 60% o más.
MX2016010541A 2014-02-14 2015-02-13 Composiciones de canabinoide y usos. MX382192B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1402678.5A GB2524469A (en) 2014-02-14 2014-02-14 A cannabinoid inhaler and composition therefor
US201461941724P 2014-02-19 2014-02-19
GB1420943.1A GB2525269A (en) 2014-02-14 2014-11-25 Cannabinoid compositions and uses
PCT/GB2015/050418 WO2015121673A1 (en) 2014-02-14 2015-02-13 Cannabinoid compositions and uses

Publications (2)

Publication Number Publication Date
MX2016010541A MX2016010541A (es) 2016-11-29
MX382192B true MX382192B (es) 2025-03-13

Family

ID=50440210

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010541A MX382192B (es) 2014-02-14 2015-02-13 Composiciones de canabinoide y usos.
MX2019011701A MX391861B (es) 2014-02-14 2015-02-13 Composiciones de canabinoide y usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019011701A MX391861B (es) 2014-02-14 2015-02-13 Composiciones de canabinoide y usos

Country Status (10)

Country Link
US (4) US10413521B2 (es)
EP (1) EP3104837A1 (es)
JP (2) JP6391701B2 (es)
AU (1) AU2015216718B2 (es)
CA (2) CA3014697C (es)
GB (2) GB2524469A (es)
IL (1) IL247262B (es)
MX (2) MX382192B (es)
NZ (1) NZ723838A (es)
WO (1) WO2015121673A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
CA2966710A1 (en) * 2014-11-03 2016-05-12 Ramot At Tel Aviv University Ltd. Methods for treatment of cognitive decline
JP7001589B2 (ja) 2015-07-20 2022-01-19 メディカル、ディベロップメンツ、インターナショナル、リミテッド 吸入可能な液体のための吸入器デバイス
GB2542389A (en) * 2015-09-17 2017-03-22 Kind Consumer Ltd Simulated cigarette
CN205196999U (zh) * 2015-11-23 2016-05-04 深圳市合元科技有限公司 雾化器及电子烟
WO2018152637A1 (en) * 2017-02-22 2018-08-30 Gene Bernaudo Electronic cigarette mixing agent composition systems
GB201712159D0 (en) * 2017-07-28 2017-09-13 Mexichem Fluor Sa De Cv Pharmaceutical composition
GB2567240B (en) * 2017-10-09 2022-04-06 Senzer Ltd An inhaler particularly a cannabinoid inhaler and a method of assembling such an inhaler
WO2019135224A1 (en) * 2018-01-03 2019-07-11 Icdpharma Ltd. Taste-enhanced cannabinoid submicron emulsion syrup compositions
US20220142970A1 (en) * 2019-03-24 2022-05-12 Buzzelet Development And Technologies Ltd. Cannabis inhalation products and methods of production thereof
CN110200953B (zh) * 2019-06-15 2022-02-08 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
GB2586477A (en) * 2019-08-20 2021-02-24 Mexichem Fluor Sa De Cv Composition and method
GB2588087A (en) * 2019-09-27 2021-04-21 Senzer Ltd Inhalable cannabinoid compositions and uses
JP2022550569A (ja) 2019-10-03 2022-12-02 スタートン セラピューティクス，インコーポレイティド ドロナビノールの経皮送達
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
MX2022004257A (es) 2019-10-11 2022-05-26 Pike Therapeutics Inc Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12279647B2 (en) 2019-12-23 2025-04-22 Pax Labs, Inc. Vaporizer cartridge
GB2595692B (en) 2020-06-03 2024-10-23 Senzer Ltd A refill for an inhaler particularly a cannabinoid inhaler
US20220015443A1 (en) * 2020-07-15 2022-01-20 Altria Client Services Llc Steady state resistance estimation for overheating protection of a non-nicotine e-vaping device
US11744285B2 (en) 2020-07-15 2023-09-05 Altria Client Services Llc Steady state resistance estimation for overheating protection of a nicotine e-vaping device
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
USD1028336S1 (en) 2021-06-22 2024-05-21 Pax Labs, Inc. Vaporizer cartridge
KR102824241B1 (ko) * 2022-11-01 2025-06-25 주식회사 케이티앤지 흡입기
WO2025149460A1 (en) * 2024-01-08 2025-07-17 Oxford Cannabinoid Technologies Holdings Plc Cannabinoid compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
DK1212039T3 (da) * 1999-08-20 2005-12-19 Unimed Pharmaceuticals Inc Sammensætning til inhalation omfattende delta-9-tetrahydrocannabinol i et semivandigt oplösningsmiddel
US6367471B1 (en) * 1999-11-01 2002-04-09 Sheffield Pharmaceuticals, Inc. Internal vortex mechanism for inhaler device
GB2361869B (en) 2000-03-09 2004-09-22 Pharmasol Ltd Sublingual delivery of cannabis
AU782991B2 (en) * 2000-03-09 2005-09-15 GW Research Limited Pharmaceutical compositions
EP1321159A1 (en) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
US20080159961A1 (en) * 2002-06-22 2008-07-03 Austen John Woolfe Pharmaceutical Composition
CN101203208A (zh) * 2005-06-20 2008-06-18 尤尼麦德制药公司 屈大麻酚治疗偏头痛
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
ES2441963T3 (es) * 2007-10-05 2014-02-07 Sti Pharmaceuticals Ltd. Composición farmacéutica
GB0823491D0 (en) * 2008-12-23 2009-01-28 Kind Consumer Ltd A simulated cigarette device
GB2476611B (en) * 2009-08-07 2011-08-31 Kind Consumer Ltd An inhaler
GB201003552D0 (en) * 2010-03-03 2010-04-21 Kind Consumer Ltd A simulated cigarette
GB201004861D0 (en) * 2010-03-23 2010-05-05 Kind Consumer Ltd A simulated cigarette
EP2603213A4 (en) 2010-08-09 2014-02-19 Univ Maryland METHOD FOR THE TREATMENT OF OBSTRUCTIVE LUNG DISEASES USING BITTER TASTES
WO2014006135A2 (en) * 2012-07-05 2014-01-09 Glaxo Group Limited Inhaler device
GB201215273D0 (en) * 2012-08-28 2012-10-10 Kind Consumer Ltd Nicotine composition
KR101783335B1 (ko) * 2012-08-28 2017-09-29 카인드 컨슈머 리미티드 흡입기
US10639439B2 (en) * 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof

Also Published As

Publication number Publication date
AU2015216718A1 (en) 2016-09-01
GB201402678D0 (en) 2014-04-02
NZ723838A (en) 2019-08-30
CA2939242C (en) 2018-12-18
WO2015121673A1 (en) 2015-08-20
GB201420943D0 (en) 2015-01-07
US20190358195A1 (en) 2019-11-28
IL247262A0 (en) 2016-09-29
IL247262B (en) 2020-07-30
CA2939242A1 (en) 2015-08-20
CA3014697A1 (en) 2015-08-20
GB2524469A (en) 2015-09-30
NZ754337A (en) 2021-10-29
US20200147035A1 (en) 2020-05-14
US10413521B2 (en) 2019-09-17
US20200163932A1 (en) 2020-05-28
MX2019011701A (es) 2020-01-09
AU2015216718B2 (en) 2017-11-16
US20170056368A1 (en) 2017-03-02
CA3014697C (en) 2021-05-04
JP6391701B2 (ja) 2018-09-19
JP2018150334A (ja) 2018-09-27
GB2525269A (en) 2015-10-21
EP3104837A1 (en) 2016-12-21
MX2016010541A (es) 2016-11-29
US10561634B2 (en) 2020-02-18
JP2017506639A (ja) 2017-03-09
MX391861B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
MX391861B (es) Composiciones de canabinoide y usos
PH12015500686A1 (en) Nicotine composition
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
ZA201902584B (en) Cannabis extracts and methods of preparing and using same
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
MX2021006035A (es) Formulaciones cannabinoides estables.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
EA201691808A8 (ru) Кортикостероидные композиции для местного применения
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
MX377919B (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX375427B (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion
HK1222337A1 (zh) 用於施加药物活性成分或化妆品活性成分的局部组合物和载体
MX2016001422A (es) Composicion farmaceutica de fingolimod.
CO2019003761A2 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
MX2015011588A (es) Tratamiento de combinacion.
PH12019500024A1 (en) Pharmaceutical compositions
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
TH159989A (th) องค์ประกอบนิโคติน
MX381207B (es) Uso de alcoholes de azucar en composiciones de tibolona
UA106123C2 (uk) Похідні 1-(3,5-ди-трет-бутил-4-гідроксифеніл)-2-(1-арил-1н-тетразол-5-ілсульфаніл)етанону, що проявляють антиоксидантні властивості
IN2013DE00880A (es)